Use of cladribine on a stent to prevent restenosis

Details Use of cladribine on a stent to prevent restenosis Use of cladribine on a stent to prevent restenosis

A - Human Necessities

61

K

A61K 31/7076 (2006.01) A61F 2/06 (2006.01) A61L 31/16 (2006.01) A61P 9/10 (2006.01) A61P 41/00 (2006.01) A61F 2/00 (2006.01)

Patent

CA 2337565

The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of the antiproliferative antineoplastic agent, cladribine, to patients undergoing PTCA or stent implantation. In one embodiment of the invention, cladribine is administered to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, cladribine is bound to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, cladribine could be incorporated into a stent constructed with a grooved reservoir.

Affiliated with

Also associated with

Rating

Use of cladribine on a stent to prevent restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of cladribine on a stent to prevent restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cladribine on a stent to prevent restenosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2074281